Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-08-20

Clinical Trial Update: Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo [Phase 2]

View source ↗

Summary

Phase 2 trial comparing LY2140023, olanzapine, and placebo in schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LY2140023
  • olanzapine (olanzapine)

Snippet

Sponsor: Denovo Biopharma LLC | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED